XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism
29 8월 2024 - 8:00PM
XORTX Therapeutics Inc. ("
XORTX" or the
“
Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
ANU), a late-stage clinical pharmaceutical company focused on
developing innovative therapies to treat progressive kidney
disease, is pleased to report that recent peer-reviewed,
independent, published research highlights that genetic factors are
linked to the over-expression of xanthine oxidase (“XO”) and play a
role in several diseases, including kidney disease. These
ground-breaking findings further support the Company’s approach to
treating kidney and other diseases by inhibiting XO.
Xanthine oxidase is an essential enzyme within
the uric acid metabolic pathway and is required for the breakdown
of purine nucleotides. The breakdown products of XO, including uric
acid (“UA”) and reactive oxygen species (“ROS”), are released
during the enzymatic reaction and may play a detrimental role in
the circulatory system and within tissue during disease. XORTX
sponsored discoveries in rodent models of polycystic kidney disease
(“PKD”) implicate over-expression or over-activity of XO as a
potentially important target in treating this disease.
Evidence for over-expression of XO in human PKD
has not been reported to date, although work by Wang et al.
suggests linkage of genetic factors to PKD1. Recently, new emerging
discoveries link genetic factors to specific populations and show
that higher XO expression is associated with a variety of
conditions including hyperuricemia2, sepsis, organ failure and
sepsis associated acute respiratory distress syndrome (ARDS)3,4,
kidney dysfunction3,4, diabetes5, PKD1,5 and kidney failure6,7.
From a mechanistic standpoint, these studies advocate for a
precision-medicine approach in which genetic risk variants would
guide treatment decisions1.
Commenting on the research, Allen Davidoff,
Ph.D., CEO of XORTX, stated, “The combination of pioneering
research in autosomal dominant polycystic kidney disease (“ADPKD”)
sponsored by XORTX and these peer-reviewed, published research
papers support our belief that pharmacologic targeting of XO holds
enormous therapeutic potential, specifically where increased XO
activity is associated with non-diabetic or diabetic kidney
diseases. These discoveries highlight an opportunity to develop a
personalized therapeutic approach for individuals whose unique
genetic factors predisposed them to disease, and the need for
xanthine oxidase inhibition to treat those individuals at risk. We
believe that XORTX’s expertise in developing XO inhibitors,
protected by a patent portfolio that anticipated this opportunity,
combined with our therapeutic platform is ideally positioned to
deliver targeted therapeutics to individuals. Our planned clinical
trial in patients with ADPKD will test XORLO™, our proprietary
formulation of oxypurinol, and will also provide an opportunity to
further understand the role of these newly identified genetic
factors in individuals with PKD.”
References:
- Korsmo HW, Emerging roles of
xanthine oxidoreductase in chronic kidney disease, Antioxidants,
June 2024
- Major TJ, et all, Evaluation of the
diet wide contribution to serum urate levels: Met-analysis of
population based cohorts, BMJ, 363, k3952, 2018
- Gao, Li et al., Xanthine
oxidoreductase gene polymorphism are associated with high risk of
sepsis and organ failure, Respir. Res, 24, 177_2023
- Liu H, et al., Genetic variants in
XDH are associated with prognosis off gastric cancer in a Chines
population, 663, 196, 2013
- Wang et al., Genetic susceptibility
to diabetic kidney disease is linked to promoter variants
of XOR, ” The authors identified an expression quantitative
trait loci (QTL) in the cis-acting regulatory region of the
xanthine dehydrogenase, or xanthine oxidoreductase (XO), a binding
site for C/EBPβ, to be associated with diabetes-induced podocyte
loss in diabetic kidney disease in male mice. They concluded that
certain types of alleles of a gene that controls the expression of
xanthine oxidase can be over expressed in CKD, diabetic kidney
disease and polycystic kidney disease.
- Kudo M et al., Functional
Characterization of Genetic Polymorphisms Identified In the
Promotor Region of the Xanthine Oxidase Gene, Drug Metab.
Pharmacokinet., 25, 599, 2010
- Boban M, et al., Circulating purine
compound, uric acid, and xanthine oxidase/dehydrogenate
relationship in essential hypertension and end stage renal
disease., Ren. Fail., 36, 613, 2014
About XORTX Therapeutics
Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more information, please
contact:
Allen Davidoff, CEOadavidoff@xortx.com or +1 403 455 7727Kim
Golodetz, LHA Investor Relationskgolodetz@lhai.com or +1 212 838
3777 |
Nick Rigopulos, Director of Communicationsnick@alpineequityadv.com
or +1 617 901 0785 |
|
|
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied
forward-looking statements pursuant to applicable securities laws.
These forward-looking statements include, but are not limited to,
the Company's beliefs, plans, goals, objectives, expectations,
assumptions, estimates, intentions, future performance, other
statements that are not historical facts and statements identified
by words such as "expects", "anticipates", "intends", "plans",
"believes", "seeks", "estimates" or words of similar meaning. These
forward-looking statements and their implications are based on the
current expectations of the management of XORTX only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Such risks, uncertainties, and other
factors include, but are not limited to, our ability to obtain
additional financing; the accuracy of our estimates regarding
expenses, future revenues and capital requirements; the success and
timing of our preclinical studies and clinical trials; the
performance of third-party manufacturers and contract research
organizations; our plans to develop and commercialize our product
candidates; our plans to advance research in other kidney disease
applications; and, our ability to obtain and maintain intellectual
property protection for our product candidates. Except as otherwise
required by applicable law and stock exchange rules, XORTX
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties
affecting XORTX is contained under the heading “Risk Factors” in
XORTX’s Annual Report on Form 20-F filed with the SEC, which is
available on the SEC's website, www.sec.gov (including any
documents forming a part thereof or incorporated by reference
therein), as well as in our reports, public disclosure documents
and other filings with the securities commissions and other
regulatory bodies in Canada, which are available on
www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024